prognostication and initiation of therapy in polycythemia vera: do we have it right?
Published 7 years ago • 5.5K plays • Length 19:02Download video MP4
Download video MP3
Similar videos
-
17:02
indication for cytoreductive therapy in et and pv: do we have it right?
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
19:03
assessment of novel treatment options for patients with pv
-
17:25
molecular prognostication in essential thrombocythemia and polycythemia vera: does it matter?
-
19:36
evolution of the assessment of clinical benefit in polycythemia vera
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
1:12
contemporary challenges in polycythemia vera management
-
13:49
“masked” polycythemia vera and polycythemia vera “in evolution”
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
17:25
case study: inadequately controlled polycythemia vera (pv)
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
5:08
polycythemia vera - causes, symptoms, diagnosis, treatment, pathology
-
4:06
initiating treatment for polycythemia vera
-
9:43
polycythemia vera: when to move from hydroxyurea to second-line therapy
-
12:24
development of long-acting interferon as new therapy for pv and et
-
8:03
goals of therapy in polycythemia vera
-
20:53
debate: position of jak2 inhibitors as second line therapy in polycythemia vera
-
9:19
debate: should jak inhibitors use be limited to hydroxyurea-resistant/intolerant pv patients? - no